---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-316820"
form_type: "8-K"
ticker: "MPLT"
cik: "0001770069"
company_name: "MapLight Therapeutics, Inc."
filed_at: "2026-07-27T11:07:27+00:00"
generated_at: "2026-07-27T11:10:07.401196+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MapLight reports positive Phase 2 ZEPHYR results for ML-007C-MA in schizophrenia

## Summary
- Primary endpoint met: 210/3 mg BID dose showed statistically significant PANSS total score reduction vs placebo (effect size 0.37, p=0.015, LS mean diff -4.5).
- Cognitive performance improved in patients with baseline impairment (effect size 0.51, p=0.041) on prespecified secondary endpoint.
- ML-007C-MA was well tolerated with no serious or drug-related severe adverse events; all-cause discontinuation low at 19.9%.
- Company plans End-of-Phase 2 FDA meeting and additional confirmatory trial to support NDA submission.
- Also reported positive IRIS Phase 2 results for ML-004 in autism irritability; plans FDA EOP2 meeting.

## SEC filing metadata
- accession: 0001193125-26-316820
- form_type: 8-K
- ticker: MPLT
- cik: 0001770069
- company_name: MapLight Therapeutics, Inc.
- filed_at: 2026-07-27T11:07:27+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770069/000119312526316820/0001193125-26-316820-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770069/000119312526316820/d139086d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-316820
- JSON: https://secwatch.observer/filing/0001193125-26-316820.json
- Plain text: https://secwatch.observer/filing/0001193125-26-316820.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.